HURA missed EPS expectations by 47.06%
May 22, 2025, 10:32 PM
0.00%
What does HURA do
Kintara Therapeutics, a biopharmaceutical company based in San Diego, develops new cancer therapies, including the late-stage REM-001 for cutaneous metastatic breast cancer and VAL-083 for drug-resistant solid tumors. The company went public on July 12, 2016, and has two employees.
TuHURA Biosciences (HURA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, TuHURA Biosciences's actual EPS was -$0.15, missing the estimate of -$0.10 per share, resulting in a -47.06% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.